BMS-986484 + nivolumab

**BMS-986484 + nivolumab** is an investigational combination therapy being studied for the treatment of advanced or metastatic solid tumors. BMS-986484 is a novel therapeutic agent whose precise modality and target have not been disclosed in publicly available study synopses, while nivolumab is a fully human monoclonal antibody targeting the programmed cell death protein 1 (PD-1) checkpoint receptor. The combination aims to leverage the potential direct anti-tumor effects of BMS-986484 together with the immune checkpoint inhibition activity of nivolumab, which blocks PD-1 signaling and thereby enhances anti-tumor immune responses. Trials are ongoing in multiple advanced solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable colorectal carcinoma (MSS CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN)[3][5].

Other names

BMS-986484 + Opdivo